Thiogenesis Therapeutics Announces Investigator-Initiated Study in Nephropathic Cystinosis and Provides Program Update

Core Viewpoint - Thiogenesis Therapeutics is advancing its nephropathic cystinosis program with a new investigator-initiated study for its lead product candidate TTI-0102, aimed at improving treatment adherence and patient quality of life [1][10]. Company Overview - Thiogenesis Therapeutics, Corp. is a clinical-stage biotechnology company focused on developing sulfur-based prodrugs for rare pediatric diseases, with operations based in San Diego, California [14]. - The company is publicly traded on the TSX Venture Exchange and OTCQX [14]. Product Development - TTI-0102 is a next-generation cysteamine-based prodrug designed to provide sustained cysteamine exposure with lower peak plasma concentrations, allowing for once-daily oral dosing [5][13]. - The product aims to address limitations of current cysteamine therapies, which include frequent dosing and gastrointestinal intolerance [4][10]. Clinical Study - The investigator-initiated study (IIS) will evaluate TTI-0102 in patients with nephropathic cystinosis, focusing on once-daily dosing, tolerability, and white blood cell (WBC) cystine control [2][10]. - Data from this study is expected to support dose optimization and inform the planned Phase 3 pivotal program [2][6]. Regulatory Pathway - Thiogenesis is preparing to scale up manufacturing for a newly patented salt formulation of TTI-0102, which is necessary for clinical material and stability testing [6]. - The company plans to initiate a Phase 3 pivotal, non-inferiority study comparing TTI-0102 to an approved cysteamine therapy under the FDA's 505(b)(2) regulatory pathway [7]. Market Opportunity - Nephropathic cystinosis affects an estimated 2,000–2,500 patients globally, representing a market opportunity exceeding $300 million [12]. - Current cysteamine therapies face significant challenges in tolerability and adherence, indicating a strong unmet medical need [12].